Cancer Immunotherapy Trials Network


Corporate Entities

CITN is committed, along with its strategic industry partners to develop effective and innovative immunotherapy drugs to treat cancer patients. Toward this goal, CITN will develop trials of promising agents that focus on the quickest route to proof of concept, patient benefit, and regulatory approval.

By aligning the scientific, clinical and management resources of CITN and the biopharmaceutical partners, we can create unique synergy to advance promising immunotherapy compounds to the clinic more quickly, efficiently and cost effectively.

The CITN network of immunotherapy investigators are well established and recognized academic leaders in the field of immunology. Our industry partners will have access to the CITN infrastructure, which supports immunotherapy drug development from concept to demonstration of patient benefit and identification of paths to approval such as:

CITN infrastructure support for industry partners

  • Consultation by recognized immunotherapy leaders on optimal clinical trial design, including correlative study design
  • Input from opinion leaders to develop clinical pathways and regulatory schema
  • Access to an established network of highly qualified and experienced clinical sites in North America
  • Milestone-driven protocol development and completion timelines
  • A turn-key operation with scientific credibility and a clinical trial management team
  • Rapid patient accrual through CITN member sites
  • Cost savings by sharing resources among the participating network sites
  • Patient data acquisition and analysis through our electronic database system
  • Centralized services for immune-monitoring
  • Bio-specimen collection and tissue banking support
  • Training and monitoring at member sites
  • Study analysis, statistical validation and publication support

The CITN welcomes the opportunity to discuss alliance strategies and scientific advisory roles with members of the biopharmaceutical industry for compounds that have demonstrated cancer immune activity.